Safety and Efficacy of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

被引：0

作者：

Nicholls, Stephen ^{[1
]}

Nelson, Adam ^{[1
]}

Ditmarsch, Marc ^{[2
]}

Kastelein, John ^{[2
]}

Ballantyne, Christie ^{[3
]}

Ray, Kausik ^{[4
]}

Navar, Ann Marie ^{[5
]}

Nissen, Steven ^{[6
]}

Goldberg, Anne ^{[7
]}

Brunham, Liam ^{[8
]}

Wuerdeman, Erin ^{[9
]}

Neild, Annie ^{[10
]}

Kling, Douglas ^{[11
]}

Hsieh, Andrew ^{[12
]}

Ference, Brian ^{[13
]}

Laufs, Ulrich ^{[14
]}

Banach, Maciej ^{[15
]}

Mehran, Roxana ^{[16
]}

Catapano, Alberico ^{[17
]}

Davidson, Michael ^{[2
]}

机构：

[1] Victorian Heart Hosp, Clayton, Vic, Australia

[2] New Amsterdam Pharma, Amsterdam, Netherlands

[3] Baylor Coll Med, Houston, TX 77030 USA

[4] Imperial Coll London, London, England

[5] UT Southwestern Med Ctr, Dallas, TX USA

[6] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA

[7] Washington Univ, Sch Med, St Louis, MO USA

[8] Univ British C0lumbia, Vancouver, BC, Canada

[9] NewAmsterdam Pharma, Cincinnati, OH USA

[10] NewAmsterdam Pharma, Aventura, FL USA

[11] NewAmsterdam Pharma, Lebanon, NJ USA

[12] Univ Illinois, Long Grove, IL USA

[13] Deep Causal AI, Cambridge, England

[14] Univ Clin Leipzig, Leipzig, Germany

[15] Med Univ Lodz, Lodz, Poland

[16] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[17] Univ Milan, Milan, Italy

来源：

CIRCULATION | 2024年 / 150卷 / 25期

关键词：

CETP inhibitors; Lipids; Clinical trials; Dyslipidemia; Prevention;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4171281

引用

页码：E729 / E730

页数：2

共 50 条

[41] Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia
Skoumas, Loannis
Masoura, Constantina
Pitsavos, Christos
Tousoulis, Dimitris
Papadimitriou, Larnbros
Aznaouridis, Konstantinos
Chrysohoou, Christina
Giotsas, Nikolaos
Toutouza, Marina
Tentolounis, Costas
Antonlades, Charalarnbos
Stefanadis, Christodoulos
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 121 (02) : 178 - 183
[42] Pediatric heterozygous familial hypercholesterolemia patients have locally increased aortic pulse wave velocity and wall thickness at the aortic root
Tran, Andrew
Burkhardt, Barbara
Tandon, Animesh
Blumenschein, Sarah
van Engelen, Arna
Cecelja, Marina
Zhang, Song
Uribe, Sergio
Mura, Joaquin
Greil, Gerald
Hussain, Tarique
INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2019, 35 (10) : 1903 - 1911
[43] Comparative Efficacy and Safety of Low-Dose Pitavastatin Versus Atorvastatin in Patients with Hypercholesterolemia
Sansanayudh, Nakarin
Wongwiwatthananukit, Supakit
Putwai, Pawat
Dhumma-Upakorn, Rawadee
ANNALS OF PHARMACOTHERAPY, 2010, 44 (03) : 415 - 423
[44] RETRACTED: A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia (Retracted Article)
Ge, Xiaoyue
Zhu, Tiantian
Zeng, Hao
Yu, Xin
Li, Juan
Xie, Shanshan
Wan, Jinjin
Yang, Huiyao
Huang, Keke
Zhang, Weifang
BIOMED RESEARCH INTERNATIONAL, 2021, 2021
[45] Coronary Artery Calcium Score in Patients With Heterozygous Familial Hypercholesterolemia is Proportional to Lifetime LDL Burden After up to 28 Years of Treatment
Duell, P. Barton
CIRCULATION, 2013, 128 (22)
[46] Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis
Barkas, Fotios
Elisaf, Moses
Milionis, Haralampos
ATHEROSCLEROSIS, 2015, 243 (01) : 60 - 64
[47] Use of PCSK9 Inhibitor in a Mexican Boy with Compound Heterozygous Familial Hypercholesterolemia: A Case Report
Juan Ceballos-Macias, Jose
Madriz-Prado, Ramon
Vazquez Cardenas, Norma Alejandra
Aguilar-Salinas, Carlos
Teresa Tusie-Luna, Maria
Alberto Flores-Real, Jorge
Ortega-Gutierrez, Guillermo
Vargas-Sanchez, Joel
Lara-Sanchez, Carolina
Hernandez-Moreno, Alfredo
JOURNAL OF THE ENDOCRINE SOCIETY, 2020, 4 (02)
[48] Efficacy and safety of statin therapy in children with familial hypercholesterolemia -: A randomized, double-blind, placebo-controlled trial with simvastatin
de Jongh, S
Ose, L
Szamosi, T
Gagné, C
Lambert, M
Scott, R
Perron, P
Dobbelaere, D
Saborio, M
Tuohy, MB
Stepanavage, M
Sapre, A
Gumbiner, B
Mercuri, M
van Trotsenburg, ASP
Bakker, HD
Kastelein, JJP
CIRCULATION, 2002, 106 (17) : 2231 - 2237
[49] Apheresis in Homozygous Familial Hypercholesterolemia - Results of 35 Years of Follow-Up of All Norwegian Patients with Homozygous Familial Hypercholesterolemia
Bogsrud, Martin P.
Graesdal, Asgeir
Holven, Kirsten B.
Nenseter, Marit S.
Narverud, Ingunn
Langslet, Gisle
Brekke, Magne
Retterstol, Kjetil
Arnesen, Kjell-Erik
Ose, Leiv
CIRCULATION, 2011, 124 (21)
[50] Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?
Nicholls, Stephen J.
Tan, Sean
Butters, Julie
Nelson, Adam J.
EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (14) : 1879 - 1885

← 1 2 3 4 5 →